

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

RECEIVED
TECH CENTER 1600/2900
02 JAN - 7 PM 12:50

In re Application of)
ANDREW J. DANNENBERG)
Patent Application No.: 09/554,604)
Filed: May 31, 2000)
For: CYCLOOXYGENASE-2 INHIBITION)

Group Art Unit: 1617

Examiner: S. Wang

Honorable Commissioner of Patents and Trademarks
Washington, D.C. 20231

RECEIVED

JAN 1 0 2002

TECH CENTER 1600/2900

Sir:

Transmitted herewith is an amendment in the above identified application.

(X) No additional fee is required.

() An extension of a shortened statutory time for response under 37 CFR 1.136(a) is requested.

(X) This application has small entity status.

CLAIMS AS AMENDED						
	Claims Remaining after Amend.	Highest Number Paid For	Extra	RATE		Amount
				Large Entity	Small Entity	
No. of Claims in Excess of 20				18.00	9.00	
Independent Claims in Excess of 3				84.00	42.00	
First Presentation of Multiple Dependent Claims				280.00	140.00	
Extension Fee						
() One month				110.00	55.00	
() Two Months				400.00	200.00	
() Three Months				920.00	460.00	
() Four Months				1,440.00	720.00	
() Five Months				1,960.00	980.00	


TOTAL FEE \$ NONE

- ☐ A check in the amount of \$ _____ is attached. (Check No. _____)
- ☐ Charge \$ _____ to Deposit Account No. 10-1213. A duplicate of this sheet is enclosed.
- ☒ The Commissioner is hereby authorized to charge payment of the following fees during the pendency of this application or credit any overpayment to Deposit Account No. 10-1213. A duplicate of this sheet is enclosed.
- ☒ Any patent application processing fees under 37 CFR 1.17.
- ☒ Any filing fees under 37 CFR 1.16 for presentation of extra claims.

Respectfully submitted,

JONES, TULLAR & COOPER, P.C.

By: _____


Eric S. Spector
Reg. No. 22,495

JONES, TULLAR & COOPER, P.C.
P.O. Box 2266 Eads Station
Arlington, Virginia 22202
703-415-1500

Date: January 7, 2002

Case: CRF D-2165

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Application of)

ANDREW J. DANNENBERG)

Patent Application No. 09/554,604)

Filed: May 31, 2000)

For: CYCLOOXYGENASE-2 INHIBITION)

Group Art Unit 1617

Examiner: S. Wang

RECEIVED
TECH CENTER 1600/2900
02 JAN - 7 FILED
1-11-02

RESPONSIVE AMENDMENT

Honorable Assistant Commissioner for Patents
Washington, D.C. 20231

Sir:

RECEIVED

JAN 10 2002

TECH CENTER 1600/2900

This is in response to the Office Action of November 15, 2001.

Please amend the above-identified application as follows:

IN THE CLAIMS:

Amend Claim 1 to be as follows:

B1
1 (amended). A method of treating a patient with a liver disease comprising administering to said patient a cyclooxygenase-2 inhibiting amount of a selective inhibitor of cyclooxygenase-2 without administration of leukotriene B₄ receptor antagonist.

Amend Claim 3 to be as follows:

B2
3 (amended). A method of treating a patient affected with liver disease selected from the group consisting of chronic viral hepatitis B, chronic viral hepatitis C, alcoholic liver injury and nonalcoholic steatohepatitis, comprising administering to said patient a cyclooxygenase-2 inhibiting amount of a selective inhibitor of cyclooxygenase-2.